PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17015278-1	2006	RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), which is currently in clinical trials, is a diaziridinyl benzoquinone bioreductive anticancer drug that was designed to be activated by the obligate two-electron reductive enzyme NAD(P)H quinone oxidoreductase 1 (NQO1).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	247-279	
17015278-1	2006	RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), which is currently in clinical trials, is a diaziridinyl benzoquinone bioreductive anticancer drug that was designed to be activated by the obligate two-electron reductive enzyme NAD(P)H quinone oxidoreductase 1 (NQO1).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	281-285	
17015278-1	2006	RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), which is currently in clinical trials, is a diaziridinyl benzoquinone bioreductive anticancer drug that was designed to be activated by the obligate two-electron reductive enzyme NAD(P)H quinone oxidoreductase 1 (NQO1).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	5-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	247-279	
17015278-1	2006	RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), which is currently in clinical trials, is a diaziridinyl benzoquinone bioreductive anticancer drug that was designed to be activated by the obligate two-electron reductive enzyme NAD(P)H quinone oxidoreductase 1 (NQO1).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	5-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	281-285	
21250978-13	2011	CONCLUSIONS AND IMPLICATIONS: 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone activated JNK, resulting in mitochondria-mediated apoptotic cell death that was NQO1-dependent.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	30-90	NAD(P)H quinone dehydrogenase 1	Homo sapiens	171-175	
15746574-3	2005	RH1 [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone], presently in late preclinical and entering early clinical development, has been previously considered to be an excellent substrate for activation by NQO1.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	217-221	
15746574-3	2005	RH1 [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone], presently in late preclinical and entering early clinical development, has been previously considered to be an excellent substrate for activation by NQO1.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	5-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	217-221	
10718341-1	2000	RH1 (2,5-diaziridinyl-3-(hydroxylmethyl)-6-methyl-1,4-benzoquinone) has shown preferential activity against human tumour cell lines which express high levels of DTD (EC 1.6.99.2; NAD(P)H:quinone oxidoreductase, NQO1, DT-diaphorase) and is a candidate for clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	211-215	
10718341-1	2000	RH1 (2,5-diaziridinyl-3-(hydroxylmethyl)-6-methyl-1,4-benzoquinone) has shown preferential activity against human tumour cell lines which express high levels of DTD (EC 1.6.99.2; NAD(P)H:quinone oxidoreductase, NQO1, DT-diaphorase) and is a candidate for clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	217-230	
26424559-5	2015	On the other hand, NQO1-mediated two-electron reduction converts certain quinone compounds (such as mitomycin C, E09, RH1 and  -lapachone) to cytotoxic agents, leading to cell death.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	118-121	NAD(P)H quinone dehydrogenase 1	Homo sapiens	19-23	
15554240-7	2004	NQO1 can also be exploited in the design of NQO1-directed antitumor agents such as the new aziridinylbenzoquinone RH1 and Hsp90 inhibitors such as 17AAG.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	91-117	NAD(P)H quinone dehydrogenase 1	Homo sapiens	0-4	
15554240-7	2004	NQO1 can also be exploited in the design of NQO1-directed antitumor agents such as the new aziridinylbenzoquinone RH1 and Hsp90 inhibitors such as 17AAG.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	91-117	NAD(P)H quinone dehydrogenase 1	Homo sapiens	44-48	
15131056-1	2004	PURPOSE: The purpose of our study was to develop and validate an isogenic cell line pair that differs only in the expression of NAD(P)H:quinone oxidoreductase (NQO1) that can be used to examine the in vitro and in vivo role of NQO1 in the bioactivation of the antitumor quinone RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), a compound currently in Phase I clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	278-281	NAD(P)H quinone dehydrogenase 1	Homo sapiens	160-164	
15131056-1	2004	PURPOSE: The purpose of our study was to develop and validate an isogenic cell line pair that differs only in the expression of NAD(P)H:quinone oxidoreductase (NQO1) that can be used to examine the in vitro and in vivo role of NQO1 in the bioactivation of the antitumor quinone RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), a compound currently in Phase I clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	283-343	NAD(P)H quinone dehydrogenase 1	Homo sapiens	160-164	
14666706-5	2003	Greater antitumour activity was recorded in the xenografts expressing high levels of DT-diaphorase (e.g. NX002, DT-diaphorase activity, 303 +/- 52 nmol/min/mg, T/C to MeDZQ, 33.3% and to RH1, 43.4%).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	187-190	NAD(P)H quinone dehydrogenase 1	Homo sapiens	85-98	
11248489-1	2001	RH1, 3-methyl-6-hydroxymethyl-2,5-diaziridinyl-1,4-benzoquinone, is a NQO1 (NAD(P)H quinone oxidoreductase) directed anti-tumor agent.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	70-74	
9865924-0	1998	A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	142-145	NAD(P)H quinone dehydrogenase 1	Homo sapiens	59-63	
9865924-0	1998	A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	142-145	NAD(P)H quinone dehydrogenase 1	Homo sapiens	152-156	
9865924-4	1998	RH1, a water-soluble analogue of MeDZQ synthesized in this work, was a better substrate for recombinant human NQO1 than the parent compound.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-3	NAD(P)H quinone dehydrogenase 1	Homo sapiens	110-114	
9865924-9	1998	In comparison to the parental cell line, RH1, MeDZQ, and mitomycin C were significantly more cytotoxic to BE-NQ7 cells (17-, 7-, and 3-fold, respectively), confirming that the presence of NQO1 is sufficient to increase cytotoxicity of these antitumor quinones.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	41-44	NAD(P)H quinone dehydrogenase 1	Homo sapiens	188-192	
21250978-1	2011	BACKGROUND AND PURPOSE: 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a bioreductive agent that is activated by the two-electron reductase NAD(P)H quinone oxidoreductase 1 (NQO1).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	24-84	NAD(P)H quinone dehydrogenase 1	Homo sapiens	197-201	
21250978-1	2011	BACKGROUND AND PURPOSE: 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a bioreductive agent that is activated by the two-electron reductase NAD(P)H quinone oxidoreductase 1 (NQO1).	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	86-89	NAD(P)H quinone dehydrogenase 1	Homo sapiens	197-201	
21250978-3	2011	EXPERIMENTAL APPROACH: 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone-induced apoptosis and related signalling pathways in NQO1-negative and NQO1-overexpressing cells were evaluated.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	23-83	NAD(P)H quinone dehydrogenase 1	Homo sapiens	137-141	
21250978-3	2011	EXPERIMENTAL APPROACH: 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone-induced apoptosis and related signalling pathways in NQO1-negative and NQO1-overexpressing cells were evaluated.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	23-83	NAD(P)H quinone dehydrogenase 1	Homo sapiens	155-159	
21250978-6	2011	KEY RESULTS: 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone induced apoptosis and clonogenic death, dependent on NQO1 and p53.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	13-73	NAD(P)H quinone dehydrogenase 1	Homo sapiens	127-131	
18794327-1	2008	2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl benzoquinone derivative designed to be bioactivated by the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1) and is currently in clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	0-60	NAD(P)H quinone dehydrogenase 1	Homo sapiens	215-219	
18794327-1	2008	2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl benzoquinone derivative designed to be bioactivated by the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1) and is currently in clinical trials.	2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone	62-65	NAD(P)H quinone dehydrogenase 1	Homo sapiens	215-219